0001493152-26-022610
SEC filingAbeona Therapeutics reported $8.7 million in Q1 2026 net product revenue from ZEVASKYN, a $6.3 million quarter-over-quarter increase, alongside a $17.1 million net loss and $168.3 million in cash as of March 31, 2026, while advancing ABO-701 toward an IND filing in H2 2027 and deprioritizing ophthalmology programs.
Abeona’s Q1 2026 results reflect its transition into a commercial-stage biopharma company following the April 2025 FDA approval of ZEVASKYN, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Revenue growth — $8.7M in net product revenue, up $6.3M sequentially — was directly tied to increased patient treatment volume (three completed in Q1 vs. one in Q4 2025) and expansion of the Qualified Treatment Center (QTC) network to six sites, including high-profile additions on the East Coast. Cost of sales rose proportionally with manufacturing scale-up, while R&D expenses declined year-over-year excluding a $7.0M up-front payment for the PSMA-SIR-T™ platform (now ABO-701), underscoring the shift of production-related costs out of R&D post-approval. SG&A more than doubled to $19.5M, driven by commercial infrastructure build-out: $5.4M in personnel and stock compensation, $1.9M in reclassified engineering/training costs, and other launch-related expenditures. The $17.1M net loss reflects this strategic investment phase. Cash decreased by $23.1M quarter-over-quarter to $168.3M — sufficient to fund operations through anticipated milestones, including the planned H2 2027 IND filing for ABO-701. Management emphasized sustained commercial momentum, citing 95% U.S. commercial insurance coverage and upcoming data presentations at SID2026, while explicitly deprioritizing ophthalmology programs to concentrate resources on ZEVASKYN commercialization and ABO-701 development — a clear portfolio rationalization aligned with near-term revenue generation and long-term pipeline differentiation in solid tumors.